CTI BioPharma Corp. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
34,678.00
60,077.00
16,116.00
57,405.00
25,146.00
26,290
Cost of Goods Sold (COGS) incl. D&A
1,707.00
1,995.00
1,940.00
1,377.00
1,081.00
879
Gross Income
32,971.00
58,082.00
14,176.00
56,028.00
24,065.00
25,411
SG&A Expense
74,342.00
119,737.00
130,589.00
110,267.00
61,384.00
57,650
EBIT
41,371.00
64,374.00
-
55,062.00
37,319.00
32,239
Unusual Expense
155.00
21,859.00
-
5,900.00
2,300.00
660
Non Operating Income/Expense
485.00
5,320.00
1,603.00
963.00
823.00
4,062
Interest Expense
1,539.00
2,676.00
2,494.00
2,828.00
2,035.00
1,734
Pretax Income
43,550.00
94,229.00
120,763.00
52,953.00
40,831.00
29,352
Consolidated Net Income
43,550.00
94,229.00
120,763.00
52,953.00
40,831.00
29,352
Net Income
42,743.00
93,367.00
119,422.00
52,009.00
40,670.00
29,320
Net Income After Extraordinaries
42,743.00
93,367.00
119,422.00
52,009.00
40,670.00
29,320
Net Income Available to Common
49,643.00
95,992.00
122,622.00
52,009.00
45,020.00
29,400
EPS (Basic)
4.30
6.50
6.51
1.86
1.24
0.52
Basic Shares Outstanding
11,419.50
14,853.10
18,837.00
27,948.00
36,445.00
56,073
EPS (Diluted)
4.35
6.46
6.51
1.86
1.24
0.52
Diluted Shares Outstanding
11,419.50
14,853.10
18,837.00
27,948.00
36,445.00
56,073
EBITDA
39,801.00
63,274.00
115,676.00
54,231.00
36,602.00
31,646
Other Operating Expense
-
2,719.00
253.00
823.00
-
-
Minority Interest Expense
807.00
862.00
1,341.00
944.00
161.00
32
Preferred Dividends
6,900.00
2,625.00
3,200.00
-
4,350.00
80
About CTI BioPharma
View Profile
